-
2
-
-
0025253463
-
Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials
-
Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med. 1990;322:1021-7.
-
(1990)
N Engl J Med
, vol.322
, pp. 1021-1027
-
-
Young, R.C.1
Walton, L.A.2
Ellenberg, S.S.3
-
3
-
-
0027395983
-
Second-line chemotherapy for recurrent carcinoma of the ovary
-
Thigpen JT, Vance RB, Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer. 1993;71(4 suppl):1559-64.
-
(1993)
Cancer
, vol.71
, Issue.4 SUPPL.
, pp. 1559-1564
-
-
Thigpen, J.T.1
Vance, R.B.2
Khansur, T.3
-
4
-
-
4143087249
-
Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: Implications for patient management and clinical trial design
-
Markman M, Markman J, Webster K, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol. 2004;22:3120-5.
-
(2004)
J Clin Oncol
, vol.22
, pp. 3120-3125
-
-
Markman, M.1
Markman, J.2
Webster, K.3
-
5
-
-
1542364058
-
Predicting the effectiveness of chemotherapy (Cx) in patients with recurrent ovarian cancer (ROC): A GINECO study
-
Abstr
-
Pujade-Lauraine E, Paraiso D, Cure H, et al. Predicting the effectiveness of chemotherapy (Cx) in patients with recurrent ovarian cancer (ROC): a GINECO study. J Clin Oncol. 2002;21:Abstr 829.
-
(2002)
J Clin Oncol
, vol.21
, pp. 829
-
-
Pujade-Lauraine, E.1
Paraiso, D.2
Cure, H.3
-
6
-
-
33644516543
-
Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range
-
Santillan A, Garg R, Zahurak ML, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol. 2005;23:9338-43.
-
(2005)
J Clin Oncol
, vol.23
, pp. 9338-9343
-
-
Santillan, A.1
Garg, R.2
Zahurak, M.L.3
-
7
-
-
34548513054
-
An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy
-
Liu PY, Alberts DS, Monk BJ, et al. An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol. 2007; 25:3615-20.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3615-3620
-
-
Liu, P.Y.1
Alberts, D.S.2
Monk, B.J.3
-
8
-
-
0034692452
-
New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup
-
Vergote I, Rustin GJ, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst. 2000;92:1534-5.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 1534-1535
-
-
Vergote, I.1
Rustin, G.J.2
Eisenhauer, E.A.3
-
9
-
-
0035281501
-
Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer
-
Doyle C, Crump M, Pintilie M, Oza AM. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol. 2001;19:1266-74.
-
(2001)
J Clin Oncol
, vol.19
, pp. 1266-1274
-
-
Doyle, C.1
Crump, M.2
Pintilie, M.3
Oza, A.M.4
-
10
-
-
0036498921
-
Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubucin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens
-
Cantu MG, Buda A, Parma G, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubucin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol. 2002; 20:1232-7.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1232-1237
-
-
Cantu, M.G.1
Buda, A.2
Parma, G.3
-
11
-
-
0026086870
-
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin
-
Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991; 9:389-93.
-
(1991)
J Clin Oncol
, vol.9
, pp. 389-393
-
-
Markman, M.1
Rothman, R.2
Hakes, T.3
-
12
-
-
34548150183
-
Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: A phase II study
-
Ferrandina G, Ludovisi M, De Vicenzo R, et al. Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. Ann Oncol. 2007;18:1348-53.
-
(2007)
Ann Oncol
, vol.18
, pp. 1348-1353
-
-
Ferrandina, G.1
Ludovisi, M.2
de Vicenzo, R.3
-
13
-
-
19744368302
-
Cancer of the ovary
-
Canistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519-29.
-
(2004)
N Engl J Med
, vol.351
, pp. 2519-2529
-
-
Canistra, S.A.1
-
14
-
-
68749099837
-
A randomized trial in ovarian cancer (OC) or early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials)
-
Abstr
-
Rustin GJ, van der Burg ME, et al. A randomized trial in ovarian cancer (OC) or early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). J Clin Oncol. 2009; 27(18 suppl):Abstr 1.
-
(2009)
J Clin Oncol
, vol.27
, Issue.18 SUPPL.
, pp. 1
-
-
Rustin, G.J.1
van der Burg, M.E.2
-
15
-
-
0036498921
-
Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens
-
Cantù MG, Buda A, Parma G, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol. 2002;20:1232-7.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1232-1237
-
-
Cantù, M.G.1
Buda, A.2
Parma, G.3
-
16
-
-
0036499081
-
Is there a best choice of second-line agent in thetreatment of recurrent, potentially platinum-sensitive ovarian cancer?
-
Cannistra SA. Is there a best choice of second-line agent in thetreatment of recurrent, potentially platinum-sensitive ovarian cancer? J Clin Oncol. 2002; 20:1158-60.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1158-1160
-
-
Cannistra, S.A.1
-
17
-
-
0037862963
-
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2-2 trial
-
Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2-2 trial. Lancet. 2003;361:2099-2106.
-
(2003)
Lancet
, vol.361
, pp. 2099-2106
-
-
Parmar, M.K.1
Ledermann, J.A.2
Colombo, N.3
-
18
-
-
33750588670
-
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG
-
Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699-4707.
-
(2006)
J Clin Oncol
, vol.24
, pp. 4699-4707
-
-
Pfisterer, J.1
Plante, M.2
Vergote, I.3
-
19
-
-
68749121487
-
A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC). CALYPSO study of the Gynecologic Cancer Intergroup (GCIG)
-
Abstr
-
Pujade-Lauraine E, Mahner S, Kaem J, et al. A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC). CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). J Clin Oncol. 2009;27:(18 suppl): Abstr LBA5509.
-
(2009)
J Clin Oncol
, vol.27
, Issue.18 SUPPL.
-
-
Pujade-Lauraine, E.1
Mahner, S.2
Kaem, J.3
-
20
-
-
36849019301
-
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A GOG study
-
Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a GOG study. J Clin Oncol. 2007;25:5165-71.
-
(2007)
J Clin Oncol
, vol.25
, pp. 5165-5171
-
-
Burger, R.A.1
Sill, M.W.2
Monk, B.J.3
-
21
-
-
37849035249
-
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital Phase II consortia
-
Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital Phase II consortia. J Clin Oncol. 2008;26:76-82.
-
(2008)
J Clin Oncol
, vol.26
, pp. 76-82
-
-
Garcia, A.A.1
Hirte, H.2
Fleming, G.3
-
22
-
-
36849056497
-
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
-
Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180-6.
-
(2007)
J Clin Oncol
, vol.25
, pp. 5180-5186
-
-
Cannistra, S.A.1
Matulonis, U.A.2
Penson, R.T.3
-
23
-
-
84876471650
-
-
Presented at the 2012 SGO Annual Meeting, Austin, TX: Abstr
-
Aghajanian C, Blank S, Goff B, et al. Results from a 2nd interim OS analysis in OCEANS, a randomized phase 3 trial of gemcitabine (G), carboplatin (C) and bevacizumab (BV) followed by BV to disease progression in patients with platinum-sensitive recurrent epithelial ovarian (OC), primary peritoneal (PPC), or fallopian tube cancer (FTC). Presented at the 2012 SGO Annual Meeting, Austin, TX: Abstr 2289.
-
Results From a 2nd Interim OS Analysis In OCEANS, a Randomized Phase 3 Trial of Gemcitabine (G), Carboplatin (C) and Bevacizumab (BV) Followed By BV to Disease Progression In Patients With Platinum-sensitive Recurrent Epithelial Ovarian (OC), Primary Peritoneal (PPC), Or Fallopian Tube Cancer (FTC)
, pp. 2289
-
-
Aghajanian, C.1
Blank, S.2
Goff, B.3
-
24
-
-
84861736119
-
OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC)
-
Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol. 2012;30:2039.
-
J Clin Oncol
, vol.2012
, pp. 30
-
-
Aghajanian, C.1
Blank, S.V.2
Goff, B.A.3
-
25
-
-
78649361197
-
A randomized phase III study of trabectedin with pegulated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer
-
Stockholm, Sweden, Abstr
-
Monk BJ, Herzog T, Kaye S, et al. A randomized phase III study of trabectedin with pegulated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer. Proceedings of the 33rd ESMO Congress, Stockholm, Sweden, 2008:Abstr LBA4.
-
(2008)
Proceedings of the 33rd ESMO Congress
-
-
Monk, B.J.1
Herzog, T.2
Kaye, S.3
-
26
-
-
34648829056
-
Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening
-
Simpkins F, Belinson JL, Rose PG. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol. 2007;107:118-23.
-
(2007)
Gynecol Oncol
, vol.107
, pp. 118-123
-
-
Simpkins, F.1
Belinson, J.L.2
Rose, P.G.3
-
27
-
-
0024327106
-
Taxol: A unique antineoplastic agent with significant activity in advanced ovarian adenocarcinoma
-
McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian adenocarcinoma. Ann Intern Med. 1989;111:273-9.
-
(1989)
Ann Intern Med
, vol.111
, pp. 273-279
-
-
McGuire, W.P.1
Rowinsky, E.K.2
Rosenshein, N.B.3
-
28
-
-
0027055485
-
Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma
-
Einzig AI, Wiernik PH, Sasloff J, et al. Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol. 1992;10:1748-53.
-
(1992)
J Clin Oncol
, vol.10
, pp. 1748-1753
-
-
Einzig, A.I.1
Wiernik, P.H.2
Sasloff, J.3
-
29
-
-
0028153230
-
Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A GOG study
-
Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a GOG study. J Clin Oncol. 1994;12:1748-53.
-
(1994)
J Clin Oncol
, vol.12
, pp. 1748-1753
-
-
Thigpen, J.T.1
Blessing, J.A.2
Ball, H.3
-
30
-
-
0028078681
-
Dose-intense taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer
-
Kohn EC, Sarosy G, Bicher A, et al. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst. 1994;86:18-24.
-
(1994)
J Natl Cancer Inst
, vol.86
, pp. 18-24
-
-
Kohn, E.C.1
Sarosy, G.2
Bicher, A.3
-
31
-
-
0028020890
-
Phase II study of gemcitabine (2,2-difluorodeoxycytidine) in previously treated ovarian cancer patients
-
Lund B, Hansen OP, Theilade K, et al. Phase II study of gemcitabine (2,2-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst. 1994;86:1530-3.
-
(1994)
J Natl Cancer Inst
, vol.86
, pp. 1530-1533
-
-
Lund, B.1
Hansen, O.P.2
Theilade, K.3
-
32
-
-
34447570846
-
Randomized phase III trial of gemcitabine compared to pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
-
Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared to pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25:2811-8.
-
(2007)
J Clin Oncol
, vol.25
, pp. 2811-2818
-
-
Mutch, D.G.1
Orlando, M.2
Goss, T.3
-
33
-
-
33745994656
-
Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and resistant ovarian cancer after previous platinum-taxane therapy: A phase II Austrian AGO study
-
Petru E, Angleitner-Boubenizek L, Reinthaller A, et al. Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study. Gynecol Oncol 2006;102:226-9.
-
(2006)
Gynecol Oncol
, vol.102
, pp. 226-229
-
-
Petru, E.1
Angleitner-Boubenizek, L.2
Reinthaller, A.3
-
34
-
-
84865675658
-
Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone
-
Jul 2, Epub ahead of print
-
Krasner C, Poveda A, Herzog TJ, et al. Patient-reported outcomes in relapsed ovarian cancer: results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone. Gynecol Oncol. 2012; Jul 2. [Epub ahead of print]
-
(2012)
Gynecol Oncol
-
-
Krasner, C.1
Poveda, A.2
Herzog, T.J.3
-
35
-
-
0035879099
-
Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
-
Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312-22.
-
(2001)
J Clin Oncol
, vol.19
, pp. 3312-3322
-
-
Gordon, A.N.1
Fleagle, J.T.2
Guthrie, D.3
-
36
-
-
1542274149
-
Overall survival advantage for pegylated liposomal doxorubicin compared to topotecan in epithelial ovarian cancer
-
Abstr
-
Gordon AN, Teitelbaum A. Overall survival advantage for pegylated liposomal doxorubicin compared to topotecan in epithelial ovarian cancer. Eur J Cancer. 2003;12:Abstr S51.
-
(2003)
Eur J Cancer
, vol.12
-
-
Gordon, A.N.1
Teitelbaum, A.2
-
37
-
-
0005323412
-
A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer
-
Abstr
-
OByrne KJ, Bliss P, Graham JD, et al. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer. Proc Am Soc Clin Oncol. 2002;21:Abstr 808.
-
(2002)
Proc Am Soc Clin Oncol
, vol.21
, pp. 808
-
-
Obyrne, K.J.1
Bliss, P.2
Graham, J.D.3
-
38
-
-
0031055830
-
Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
-
Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol. 1997;15:987-93.
-
(1997)
J Clin Oncol
, vol.15
, pp. 987-993
-
-
Muggia, F.M.1
Hainsworth, J.D.2
Jeffers, S.3
-
39
-
-
0034903028
-
Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: A retrospective comparative study of single-agent dosages
-
Rose PG, Maxson JH, Fusco N, et al. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol. 2001;82:323-8.
-
(2001)
Gynecol Oncol
, vol.82
, pp. 323-328
-
-
Rose, P.G.1
Maxson, J.H.2
Fusco, N.3
-
40
-
-
9244247616
-
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma
-
Kudelka AP, Tresukosol D, Edwards CL, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol. 1996;14:1552-7.
-
(1996)
J Clin Oncol
, vol.14
, pp. 1552-1557
-
-
Kudelka, A.P.1
Tresukosol, D.2
Edwards, C.L.3
-
41
-
-
0031781459
-
Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study
-
Hoskins P, Eisenhauer E, Beare S, et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol. 1998;16:2233-7.
-
(1998)
J Clin Oncol
, vol.16
, pp. 2233-2237
-
-
Hoskins, P.1
Eisenhauer, E.2
Beare, S.3
-
42
-
-
0035060411
-
Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma
-
Sorensen P, Hoyer M, Jakobsen A, et al. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol. 2001; 81:58-62.
-
(2001)
Gynecol Oncol
, vol.81
, pp. 58-62
-
-
Sorensen, P.1
Hoyer, M.2
Jakobsen, A.3
-
43
-
-
0032936206
-
Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer
-
Burger RA, DiSaia PJ, Roberts JA, et al. Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncol. 1999;72:148-53.
-
(1999)
Gynecol Oncol
, vol.72
, pp. 148-153
-
-
Burger, R.A.1
Disaia, P.J.2
Roberts, J.A.3
-
44
-
-
0018595569
-
Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: A Gynecologic Oncology Group study
-
Slayton RE, Creasman WT, Petty W, et al. Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group study. Cancer Treat Rep. 1979;63:2089-94.
-
(1979)
Cancer Treat Rep
, vol.63
, pp. 2089-2094
-
-
Slayton, R.E.1
Creasman, W.T.2
Petty, W.3
-
45
-
-
0031894188
-
Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A GOG study
-
Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a GOG study. J Clin Oncol. 1998;16:405-10.
-
(1998)
J Clin Oncol
, vol.16
, pp. 405-410
-
-
Rose, P.G.1
Blessing, J.A.2
Mayer, A.R.3
Homesley, H.D.4
-
46
-
-
0037331627
-
A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: A Gynecologic Oncology Group study
-
Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003;88:130-5.
-
(2003)
Gynecol Oncol
, vol.88
, pp. 130-135
-
-
Rose, P.G.1
Blessing, J.A.2
Ball, H.G.3
-
47
-
-
1642264781
-
Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum
-
Markman M, Zanotti K, Webster K, et al. Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum. Gynecol Oncol. 2003;91:573-6.
-
(2003)
Gynecol Oncol
, vol.91
, pp. 573-576
-
-
Markman, M.1
Zanotti, K.2
Webster, K.3
-
48
-
-
0026599140
-
Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease
-
Markman M, Hakes T, Reichman B, et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol. 1992;10:243-8.
-
(1992)
J Clin Oncol
, vol.10
, pp. 243-248
-
-
Markman, M.1
Hakes, T.2
Reichman, B.3
-
49
-
-
77955591543
-
A phase II evaluation of pemetrexed (LY231514, IND#40061) in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the Gynecology Oncology Group
-
Abstr
-
Miller DS, Blessing JA, Krasner CN, Mannel RJ. A phase II evaluation of pemetrexed (LY231514, IND#40061) in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecology Oncology Group. J Clin Oncol. 2008;26(suppl):Abstr 5524.
-
(2008)
J Clin Oncol
, vol.26
, Issue.SUPPL.
, pp. 5524
-
-
Miller, D.S.1
Blessing, J.A.2
Krasner, C.N.3
Mannel, R.J.4
-
50
-
-
84859523588
-
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
-
Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382.
-
(2012)
N Engl J Med
, vol.366
, pp. 1382
-
-
Ledermann, J.1
Harter, P.2
Gourley, C.3
-
53
-
-
80053578082
-
A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer
-
Abstr
-
Penson RT, Whalen C, Lasonde B, et al. A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2011;29:Abstr 5004.
-
(2011)
J Clin Oncol
, vol.29
, pp. 5004
-
-
Penson, R.T.1
Whalen, C.2
Lasonde, B.3
-
54
-
-
0027999966
-
European-Candadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose verus low-dose and long versus short infusion
-
Eisenhauer EA, ten Bokkel Huinin WW, Swenerton KD, et al. European-Candadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose verus low-dose and long versus short infusion. J Clin Oncol. 1994;12:2654-66.
-
(1994)
J Clin Oncol
, vol.12
, pp. 2654-2666
-
-
Eisenhauer, E.A.1
ten Bokkel, H.W.W.2
Swenerton, K.D.3
-
55
-
-
0036570041
-
Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refactory ovarian cancer
-
Markman M, Hall J, Spitz D, et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refactory ovarian cancer. J Clin Oncol. 2002;20:2365-9.
-
(2002)
J Clin Oncol
, vol.20
, pp. 2365-2369
-
-
Markman, M.1
Hall, J.2
Spitz, D.3
-
56
-
-
10744230285
-
The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer
-
Kita L, Kikuchi Y, Takano M, et al. The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer. Gynecol Oncol. 2004;92:813-18.
-
(2004)
Gynecol Oncol
, vol.92
, pp. 813-818
-
-
Kita, L.1
Kikuchi, Y.2
Takano, M.3
-
57
-
-
33646562149
-
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study
-
Markman M, Blessing J, Rubin SC, et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;101:436-40.
-
(2006)
Gynecol Oncol
, vol.101
, pp. 436-440
-
-
Markman, M.1
Blessing, J.2
Rubin, S.C.3
-
58
-
-
0033813383
-
Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum
-
Markman M, Kennedy A, Webster K, et al. Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol. 2000;78:369-72.
-
(2000)
Gynecol Oncol
, vol.78
, pp. 369-372
-
-
Markman, M.1
Kennedy, A.2
Webster, K.3
-
60
-
-
0033995249
-
Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group study
-
McGuire WP, Blessing JA, Bookman MA, et al. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2000;18:1062-7.
-
(2000)
J Clin Oncol
, vol.18
, pp. 1062-1067
-
-
McGuire, W.P.1
Blessing, J.A.2
Bookman, M.A.3
-
61
-
-
0031786482
-
Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that combined cisplatin or carboplatin and paclitaxel
-
Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that combined cisplatin or carboplatin and paclitaxel. J Clin Oncol. 1998;16:3345-62.
-
(1998)
J Clin Oncol
, vol.16
, pp. 3345-3362
-
-
Bookman, M.A.1
Malmstrom, H.2
Bolis, G.3
-
62
-
-
9244247616
-
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma
-
Kudelka AP, Trresukosol D, Edwards CL, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol. 1996;14:1552-7.
-
(1996)
J Clin Oncol
, vol.14
, pp. 1552-1557
-
-
Kudelka, A.P.1
Trresukosol, D.2
Edwards, C.L.3
-
63
-
-
0031781459
-
Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study
-
Hoskins P, Eisenhauer E, Beare S, et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol. 1998;16:2233-7.
-
(1998)
J Clin Oncol
, vol.16
, pp. 2233-2237
-
-
Hoskins, P.1
Eisenhauer, E.2
Beare, S.3
-
64
-
-
0037331801
-
Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer
-
Brown JV, Peters WA, Rettenmaier MA, et al. Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecol Oncol. 2003;88:136-40.
-
(2003)
Gynecol Oncol
, vol.88
, pp. 136-140
-
-
Brown, J.V.1
Peters, W.A.2
Rettenmaier, M.A.3
-
65
-
-
33750191919
-
Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer
-
Herzog TJ, Powel MA, Rader JS, et al. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol. 2006;103:637-41.
-
(2006)
Gynecol Oncol
, vol.103
, pp. 637-641
-
-
Herzog, T.J.1
Powel, M.A.2
Rader, J.S.3
-
66
-
-
33947325163
-
Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer
-
Safra T, Menczer J, Bernstein R, et al. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecol Oncol. 2007;105:205-10.
-
(2007)
Gynecol Oncol
, vol.105
, pp. 205-210
-
-
Safra, T.1
Menczer, J.2
Bernstein, R.3
-
67
-
-
37349023136
-
Weekly topotecan for recurrent platinum resistant ovarian cancer
-
Abushahin G, Singh DK, Lurain JR, et al. Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecol Oncol. 2008;108:53-7.
-
(2008)
Gynecol Oncol
, vol.108
, pp. 53-57
-
-
Abushahin, G.1
Singh, D.K.2
Lurain, J.R.3
-
68
-
-
0043125703
-
Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: Results of a multicenter phase III trial in patients with advanced gynecologic malignancies
-
Gold MA, Walker JL, Berek JS, et al. Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies. Gynecol Oncol. 2003;90:325-30.
-
(2003)
Gynecol Oncol
, vol.90
, pp. 325-330
-
-
Gold, M.A.1
Walker, J.L.2
Berek, J.S.3
-
69
-
-
84866493383
-
AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)
-
Abstr
-
Pujade-Lauraine E, Hilpert F, Weber B, et al. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol. 2012;30:Abstr LBA5002.
-
(2012)
J Clin Oncol
, vol.30
-
-
Pujade-Lauraine, E.1
Hilpert, F.2
Weber, B.3
|